Back to Journals » Biologics: Targets and Therapy » Volume 3 » default

Biologics: Targets and Therapy


Archived Journals

Archive: Volume 3, 2009

Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug  Effectiveness Review Project

Kylie Thaler, Divya V Chandiramani, Richard A Hansen, et al

Biologics: Targets and Therapy 2009, 3:485-498

Published Date: 19 November 2009

Targeted therapy in melanoma

Hussein Tawbi, Neelima Nimmagadda

Biologics: Targets and Therapy 2009, 3:475-484

Published Date: 16 October 2009

Local cytokines and clinical symptoms in children with allergic rhinitis after different treatments

Gesmar RS Segundo, Fabíola A Gomes, Karla P Fernandes, et al

Biologics: Targets and Therapy 2009, 3:469-474

Published Date: 1 October 2009

Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers

Jia Li, Muhammad Wasif Saif

Biologics: Targets and Therapy 2009, 3:429-441

Published Date: 7 September 2009

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy

Bryan A Faller, Barbara Burtness

Biologics: Targets and Therapy 2009, 3:419-428

Published Date: 14 September 2009

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease

Deborah Elstein, Ari Zimran

Biologics: Targets and Therapy 2009, 3:407-417

Published Date: 31 August 2009

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma

Francesca Cainelli, Alfredo Vallone

Biologics: Targets and Therapy 2009, 3:385-390

Published Date: 17 August 2009

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis

Damiano Paolicelli, Vita Direnzo, Maria Trojano

Biologics: Targets and Therapy 2009, 3:369-376

Published Date: 13 July 2009

First-line treatment of acute lymphoblastic leukemia with pegasparaginase

Riccardo Masetti, Andrea Pession

Biologics: Targets and Therapy 2009, 3:359-368

Published Date: 7 July 2009

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

Junichiro Sageshima, Gaetano Ciancio, Linda Chen, George W Burke III

Biologics: Targets and Therapy 2009, 3:319-336

Published Date: 17 June 2009

HER2 breast cancer therapies: a review

Conleth G Murphy, Shanu Modi

Biologics: Targets and Therapy 2009, 3:289-301

Published Date: 11 June 2009

The old and new therapeutic approaches to the treatment of giardiasis: Where are we?

Haendel GNO Busatti, Joseph FG Santos, Maria A Gomes

Biologics: Targets and Therapy 2009, 3:273-287

Published Date: 5 June 2009

Early stage and long term treatment of multiple sclerosis with interferon-β

Angela Applebee, Hillel Panitch

Biologics: Targets and Therapy 2009, 3:257-271

Published Date: 28 May 2009

Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells

Arvind Kumar, Tryambak D Singh, Santosh K Singh, Satya Prakash

Biologics: Targets and Therapy 2009, 3:245-256

Published Date: 15 May 2009

Potentials and limitations of microorganisms as renal failure biotherapeutics

Poonam Jain, Sapna Shah, Razek Coussa, Satya Prakash

Biologics: Targets and Therapy 2009, 3:233-243

Published Date: 18 May 2009

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis

Joseph M Tuscano, Jacob Sands

Biologics: Targets and Therapy 2009, 3:225-232

Published Date: 13 May 2009

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab

Chad A Reade, Apar Kishor Ganti

Biologics: Targets and Therapy 2009, 3:215-224

Published Date: 11 May 2009

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

Radhakrishnan Ramchandren, Charles A Schiffer

Biologics: Targets and Therapy 2009, 3:205-214

Published Date: 8 May 2009

Infliximab in the treatment of rheumatoid arthritis

A Perdriger

Biologics: Targets and Therapy 2009, 3:183-191

Published Date: 7 May 2009

Long-term pegylated interferon-α and its potential in the treatment of melanoma

Reinhard Dummer, Joanna Mangana

Biologics: Targets and Therapy 2009, 3:169-182

Published Date: 17 April 2009

Ustekinumab in the therapy of chronic plaque psoriasis

Jenna L O’Neill, Robert E Kalb

Biologics: Targets and Therapy 2009, 3:159-168

Published Date: 25 March 2009

Management of chronic hepatitis C treatment failures: role of consensus interferon

Stevan A Gonzalez, Emmet B Keeffe

Biologics: Targets and Therapy 2009, 3:141-150

Published Date: 18 March 2009

Challenges in the management of juvenile idiopathic arthritis with etanercept

Clare E Pain, Liza J McCann

Biologics: Targets and Therapy 2009, 3:127-139

Published Date: 16 March 2009

Palifermin for management of treatment-induced oral mucositis in cancer patients

Andrei Barasch, Joel Epstein, Ken Tilashalski

Biologics: Targets and Therapy 2009, 3:111-116

Published Date: 16 February 2009

Front line treatment of elderly multiple myeloma in the era of novel agents

Marie-Dominique Venon, Aldo M Roccaro, Julie Gay, Anne-Sophie Moreau, Remy Dulery, et al

Biologics: Targets and Therapy 2009, 3:99-109

Published Date: 30 October 2008

Biologic targeting in the treatment of inflammatory bowel diseases

Matteo Bosani, Sandro Ardizzone, Gabriele Bianchi Porro

Biologics: Targets and Therapy 2009, 3:77-97

Published Date: 9 February 2009

Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency

Caitriona McLean, Catherine M Greene, Noel G McElvaney

Biologics: Targets and Therapy 2009, 3:63-75

Published Date: 21 January 2009

Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia

Eric Cheung, Howard A Liebman

Biologics: Targets and Therapy 2009, 3:57-62

Published Date: 8 January 2009

Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?

Martina Koch, Thomas Becker, Rainer Lueck, Michael Neipp, Juergen Klempnauer, Bjoern Nashan

Biologics: Targets and Therapy 2009, 3:51-56

Published Date: 12 January 2009

Maintenance treatment with infliximab for the management of Crohn’s disease in adults

Renato Caviglia, Ivo Boškoski, Michele Cicala

Biologics: Targets and Therapy 2009, 3:39-49

Published Date: 5 January 2009

Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model

Markus Scholz, Manuela Ackermann, Frank Emmrich, Markus Loeffler, Manja Kamprad

Biologics: Targets and Therapy 2009, 3:27-37

Published Date: 17 December 2008

Current available therapies and future directions in the treatment of malignant gliomas

Annick Desjardins, David A Reardon, James J Vredenburgh

Biologics: Targets and Therapy 2009, 3:15-25

Published Date: 17 December 2008

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer

Bernadette Biondi, Melania Pulcrano, Loredana Pagano, Gaetano Lombardi

Biologics: Targets and Therapy 2009, 3:9-13

Published Date: 2 December 2008